Non-Small Cell Lung Cancer

When you come to us for diagnosis or treatment for non-small cell lung cancer, you can typically see each member of our group on the same day. Your team may include pulmonologists, thoracic surgeons, medical oncologists, radiation oncologists, and interventional radiologists. This multidisciplinary team of internationally renowned experts creates a treatment plan that’s customized for you.

We use a variety of tests on tissue and blood to learn as much about the lung cancer as possible, helping us create the best treatment plan for you.

Our clinical trials can provide the newest therapeutic options, such as targeted drugs and immunotherapy. We also offer many supportive services, such as lung rehabilitation, psychological care, and integrative health therapies.

Clinical Trials and Research Studies

Phase 2

A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Learn More

Phase 2

A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)

Learn More

Phase 2

PH II study of adjuvant tx with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm) IIA IIB and select IIIA [T3N1 T4N0-1] resected NSCLC and the clearance of (ctDNA)

Learn More

Phase 5

A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER

Learn More